Meeting
2016 Gastrointestinal Cancers Symposium
Multi-institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers.
Authors
Heloisa P. Soares
Moffitt Cancer Center, Tampa, FL
Heloisa P. Soares , Nishi Kothari , Amit Mahipal , Gregory M. Springett , Jongphil Kim , Fatima Tariq , Hanna Kelly Sanoff , Andrew Stewart Poklepovic , Richard D. Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Translational Research
Clinical Trial Registration Number
NCT02115542
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr TPS468)
DOI
10.1200/jco.2016.34.4_suppl.tps468
Abstract #
TPS468
Poster Bd #
N18
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Multi institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers.
First Author: Richard D. Kim
Poster
2019 ASCO Annual Meeting
Final analysis of phase II trial of regorafenib (REG) in refractory advanced biliary cancers (BC).
First Author: Dae Won Kim
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial.
First Author: Jaekyung Cheon
Poster
2021 Gastrointestinal Cancers Symposium
DEDUCTIVE: A study of tivozanib in combination with durvalumab in subjects with untreated advanced hepatocellular carcinoma—Phase Ib results.
First Author: Renuka V. Iyer